Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;62(7):8502-8517.
doi: 10.1007/s12035-025-04750-7. Epub 2025 Feb 26.

The Role of MicroRNAs in Neurodegeneration: Insights from Huntington's Disease

Affiliations
Review

The Role of MicroRNAs in Neurodegeneration: Insights from Huntington's Disease

Reda M Mansour et al. Mol Neurobiol. 2025 Jul.

Abstract

MicroRNA (miRNAs) is a single non-coding strand with a small sequence of approximately 21-25 nucleotides, which could be a biomarker or act as a therapeutic agent for disease. This review explores the dynamic role of miRNAs in Huntington's disease (HD), encompassing their regulatory function, potential as diagnostic biomarker tools, and emerging therapeutic applications. We delved into the dysregulation of specific miRNAs in HD, for instance, downregulated levels of miR-9 and miR-124 and increased levels of miR-155 and miR-196a. These alterations highlight the promise of miRNAs as non-invasive tools for early HD detection and disease progression monitoring. Moving beyond diagnosis, the exciting potential of miRNA-based therapies. By mimicking downregulated miRNAs or inhibiting dysregulated ones, we can potentially restore the balance of mutant target gene expression and modify disease progression. Recent research using engineered miRNAs delivered via an adeno-associated virus (AAV) vector in a transgenic HD minipig model demonstrates encouraging results in reducing mutant HD and improving motor function.

Keywords: Diagnosis; Huntington’s disease; MiRNAs; Therapeutic intervention.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Competing Interests: The authors declare no competing interests.

References

    1. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of huntington’s disease: A systematic review and meta-analysis. Mov Disord 27(9):1083–1091 - PubMed
    1. Medina A, Mahjoub Y, Shaver L, Pringsheim T (2022) Prevalence and incidence of huntington’s disease: An updated systematic review and meta-analysis. Mov Disord 37(12):2327–2335 - PubMed - PMC
    1. Kay C, Hayden MR, Leavitt BR (2017) Epidemiology of Huntington disease. Handb Clin Neurol 144:31–46 - PubMed
    1. Dong X, Cong S (2021) MicroRNAs in Huntington’s disease: diagnostic biomarkers or therapeutic agents? Front Cell Neurosci 15:705348 - PubMed - PMC
    1. Irfan Z, Khanam S, Karmakar V, Firdous SM, El Khier BSIA, Khan I, Rehman MU, Khan A (2022) Pathogenesis of huntington’s disease: An emphasis on molecular pathways and prevention by natural remedies. Brain Sci 12(10):1389 - PubMed - PMC

LinkOut - more resources